Navigation Links
MU signs $5 million agreement with Coulter Translational Research Partnership Program
Date:6/21/2011

COLUMBIA, Mo. University of Missouri officials announced today a $5 million grant agreement with the Wallace H. Coulter Foundation, through the Foundation's Translational Partnership Award Program. The goal of the partnership is to develop technologies that will save, extend and improve patient lives and suffering from any disease or condition in any country around the world. The funds will be used to support collaborative projects between biomedical engineers and clinicians to take research discoveries to clinical practice.

"This is a major recognition of the University of Missouri and its researchers as only about 15 universities have been given this award," said Jinglu Tan, James C. Dowell Professor and chair of biological engineering in the College of Engineering and the College of Agriculture, Food and Natural Resources. "This award will position us to become a national leader in translational biomedical research by building on existing successes in biomedical engineering research, cooperation between engineering and medicine researchers, and technology transfer projects. This award will allow our scientists to take their discoveries and develop them for use in the hospital or other clinical settings in an effort to improve the quality of life for many people."

The agreement between MU and the Coulter Foundation stipulates that the Foundation will provide $666,667 per year for five years, while MU will match that money with $333,333 each year, for a total amount of $5 million over the next five years. An oversight committee, consisting of stake holders in translational research, will be formed to decide how to award the money to MU bioengineering faculty who are seeking to commercialize their research discoveries in partnership with clinicians.

Tan, who also is the director of the Division of Food Systems and BioEngineering; Bill Caldwell, director of Ellis Fischel Cancer Center and professor of pathology and anatomical sciences in the MU School of Medicine; and Chris Fender, director of the MU Office of Technology Management and Industrial Relations, led the MU effort for this nationwide competition. The board will consist of Tan, Caldwell, Fender, entrepreneurs, and venture capitalists.

"This program creates a framework and culture that requires physicians, scientists, and intellectual property and commercialization specialists to work together in multidisciplinary teams to take discoveries in biomedicine and transform them into viable, commercial products that address unmet clinical needs," said Caldwell, who also is the CRC Missouri Chair in Cancer Research at MU. "We truly have an enormous amount of biomedical research and intellectual property across this campus, and the Coulter award will take us much closer to developing a system for moving our research quickly into clinical practice."

Interdisciplinary efforts to take new technologies to the marketplace are numerous at MU, said Rob Duncan, vice chancellor for research. One example is the BioDesign Program, which has led to the collaboration of post-graduate fellows in medicine, engineering and business to develop and market products that are helpful for doctors. So far, the program has resulted in eight patents for new devices.

Earlier, John Viator, an associate professor of biological engineering, and two other biological engineering faculty researchers received Coulter Translational Research Awards in Biomedical Engineering. As part of his grant, Viator was provided with services that helped him take the next steps to commercializing his research. As a result, Viator has been notified that he will be granted a patent soon based on his technology that can "hear" cancer cells in the bloodstream with a laser. Currently, MU officials are working with Viator to commercialize the technology.

"These awards are very important in helping scientists understand the commercialization process," Viator said. "In my case, the award helped us develop the apparatus, define it and make it more accurate. The Coulter Foundation also provided services such as an intellectual property analysis. While one law firm studied the patent landscape regarding the technology, another firm helped us develop a business plan. We also had an opportunity to talk with other scientists who had received the award and go to seminars to learn about business and commercialization issues."

"This is affirmation and validation of our efforts toward economic development," Duncan said. "Being given this award identifies us as one of the few institutions in the country that has the resources to move new discoveries into products that will benefit health professionals and patients. The faculty and staff on our campus have worked hard and long to achieve this recognition. This is a testament to the interdisciplinary research that occurs at Mizzou."

In FY 2010, MU received more than $9.5 million in licensing revenue, which includes royalties and licensing fees. MU also licensed 38 new technologies for commercialization, and filed 57 patent applications in FY 2010. MU officials are expecting the number of new licenses to increase over the next fiscal year.


'/>"/>

Contact: Mary Jo Banken
BankenM@missouri.edu
573-882-6212
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
2. Unifying the animate and the inanimate designs of nature
3. University of Miami engineer designs stretchable electronics with a twist
4. Engineering technology pinpoints earliest signs of animal life
5. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
6. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
7. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
8. WARF signs license agreement with Pfizer for human embryonic stem cells
9. Web-based program designs more efficient farm terrace layouts
10. University has grand designs to build a house of straw
11. New DNA test uses nanotechnology to find early signs of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: